Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jazz Pharma Plc (NQ: JAZZ )

156.55 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 18, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 156.55
Bid (Size) 154.00 (1)
Ask (Size) 162.00 (1)
Prev. Close 156.55
Today's Range 156.55 - 156.55
52wk Range 117.64 - 169.98
Shares Outstanding 62,311,104
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
 
Via Benzinga
Jazz' Epidiolex, The Only FDA-Approved CBD Drug, Enters Phase 3 Trial Evaluating Its Effects In Patients With Myoclonic-Atonic Seizures
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has initiated a new Phase 3 trial to investigate the efficacy and safety of Epidiolex (cannabidiol), known as Epidyolex in Europe, in children and adolescents... 
Via Benzinga

Performance

YTD
+19.23%
+19.23%
1 Month
-1.50%
-1.50%
3 Month
+4.69%
+4.69%
6 Month
+11.11%
+11.11%
1 Year
+16.21%
+16.21%

More News

Read More
New Drugs in Pipeline for Hypertension, the Silent Global Pandemic
Via Investor Brand Network
Exposures Product Safety
Jazz Pharmaceuticals' Return On Capital Employed Insights
Via Benzinga
'Street Underestimates Jazz Pharma's Cash-Flow' Says This Analyst
Via Benzinga
Where Jazz Pharmaceuticals Stands With Analysts
Via Benzinga
New Drugs in Pipeline for Hypertension, the Silent Global Pandemic
Via FinancialNewsMedia
Exposures Product Safety
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
Via Benzinga
7 Biotech Stocks to Buy for Q3
Via InvestorPlace
Aurinia Pharmaceuticals Skids With Its Buyout Thesis Hanging By A Thread
Via Investor's Business Daily
Cannabis Stocks Struggle Through Q2 2022
Via Talk Markets
Needham Previews Neurocrine's Upcoming Mid-Stage Data from Essential Tremor Study
Via Benzinga
Brazilian Fund Invests $19M In US Cannabis Stocks
Via Benzinga
What SVB Says On Axsome's Strategy Review On Sunosi For Sleeping Disorder
Via Benzinga
Jazz Pharmaceuticals' Late-Stage Multiple Sclerosis Study Misses Primary Endpoint
Via Benzinga
Jazz Pharma's Cannabidiol Mixture Spray Misses Primary Goal In Multiple Sclerosis Spasticity
Via Benzinga
Switzerland Removes Medical Marijuana Access Limitations As Demand Rises
Via Benzinga
This Pharmaceutical Company Is Moving Beyond CBD
Via Benzinga
Leisuretown: Diplo And Rob Dyrdek's New Cannabis Seltzers Launch In California Via Agreement With HERBL
Via Benzinga
4 Analysts Have This to Say About Jazz Pharmaceuticals
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2022
Via Benzinga
Euro Food Agency Concerned About Health Effects Of CBD, Asks For More Research
Via Benzinga
North Carolina House Says Yes To Bill Allowing FDA-Approved THC Drugs, Will This Kill Full Medical Marijuana Legalization?
Via Benzinga
The Daily Biotech Pulse: Veru Seeks Emergency Use Nod For COVID-19 Therapy, Vincerx Cuts Workforce, Moderna Starts Dosing In Flu Vaccine Study
Via Benzinga
FDA Battles Over CBD Hype Yet Again, This Time Warns Businesses Selling Illegal CBD For Food-Producing Animals
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.